c-erbB-2 and Episialin Challenge Host Immune Response by HLA Class I Expression in Human Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

c-erbB-2 and Episialin Challenge Host Immune Response by HLA Class I Expression in Human Non–Small-Cell Lung Cancer

Published:2000-01 Issue:1 Volume:23 Page:104-114
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:Journal of Immunotherapy

Author:

Koukourakis Michael I.,Giatromanolaki Alexandra,Guddo Francesca,Kaklamanis Loukas,Vignola Maurizio,Kakolyris Stelios,Turley Hellen,Georgoulias Vassilios,Bonsignore Giovanni,Gatter Kevin C.,Harris Adrian L.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference59 articles.

1. The HLA system: structure and function.

2. Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer

3. c-myc down-regulates class I HLA expression in human melanomas.

4. Presence of an abnormal ? 2-microglobulin mRNA in Daudi cells: Induction by interferon

5. Selective loss of beta 2-microglobulin mRNA in human colon carcinoma.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumour Immunomodulation: Mucins in Resistance to Initiation and Maturation of Immune Response Against Tumours;Scandinavian Journal of Immunology;2013-07

2. Immune-refractory cancers and their little helpers—An extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?;Seminars in Cancer Biology;2007-12

3. HLA Class I Antigen-Processing Machinery and HLA Class I Antigen-Derived Peptide-Complex Defects in Tumor-Cell Escape;Cancer Immunotherapy at the Crossroads;2004

4. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature;British Journal of Cancer;2003-09

5. Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients;Cancer Immunology, Immunotherapy;2003-02